2,0
8. März 2016
Ehemaliger Mitarbeiter, mehr als 5 Jahre
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Novel technology, dedicated colleagues. Excellent customer base among the top Pharma companies around the world. Excellent benefits.
Kontras
After the takeover by Accelrys, the future development of the SmartLab enterprise platform was abandoned, as well as many of the employees who helped build the ELN business.